ProQR Therapeutics - PRQR Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRQR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRQR, but not buy additional shares or sell existing shares.
View PRQR analyst ratings or view top-rated stocks.

7 analysts have issued 12-month target prices for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $2.00 to $5.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 122.2% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.

ProQR Therapeutics' stock was trading at $8.01 on January 1st, 2022. Since then, PRQR shares have decreased by 83.1% and is now trading at $1.35.
View the best growth stocks for 2022 here.

ProQR Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 685,700 shares, a decrease of 34.7% from the October 31st total of 1,050,000 shares. Based on an average trading volume of 670,900 shares, the days-to-cover ratio is presently 1.0 days. Currently, 1.2% of the company's shares are sold short.
View ProQR Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PRQR earnings forecast.

ProQR Therapeutics (NASDAQ:PRQR) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.80 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 76.32% and a negative net margin of 2,075.42%.

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.83%), BlackRock Inc. (0.70%), Two Sigma Advisers LP (0.24%), Marshall Wace LLP (0.10%), Raymond James & Associates (0.07%) and Simplex Trading LLC (0.00%).

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRQR stock can currently be purchased for approximately $1.35.

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $96.24 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72,900,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

The company employs 1,504 workers across the globe.

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.